CLONING, ANALYSIS & EXPRESS OF PRIMATE CYTOKINES, CHEMOKINES, IMMUNE RECEPTORS

克隆、分析

• 批准号: 6277476
• 负责人: F VILLINGER
• 金额: $ 5.38万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6277476
• 关键词: Primates; animal tissue; biological products; biotechnology; endocrine gland /system; genetics; hematology; immunology; infection; inflammation; technology /technique

Recent therapeutic attempts include a variety of cytokines, hematopoietic growth factors, or specific ligands for the modulation of immune responses and hematopoiesis for the treatment of various clinical conditions or as adjuvant to immunization protocols. A significant number of such applications are studied using various nonhuman primate models, yet while most human factors appear biologically active in nonhuman primates, data shows that injection of human recombinant cytokines most often does not allow repeated or long-term treatment due to rapid development of an immune response towards these "foreign" molecules, resulting in inactivation and clearance of these cytokines. Furthermore the immune response of primate cells to the stimulation by certain human cytokines has been found to be markedly lower than the response of equivalent cells from human origins. These studies bear the potential to rapidly translate into therapeutic applications for the treatment of human diseases.

最近的治疗尝试包括多种细胞因子， 造血生长因子或用于调节的特异性配体 免疫反应和造血功能，用于治疗各种 临床条件或作为免疫方案的佐剂。 一 大量的这样的应用使用各种 非人类灵长类动物模型，然而，虽然大多数人类因素似乎 在非人类灵长类动物中具有生物活性，数据显示， 人重组细胞因子通常不允许重复或 由于免疫反应的快速发展而长期治疗 对这些“外来”分子，导致失活， 清除这些细胞因子。 此外， 灵长类动物细胞对某些人类细胞因子刺激的反应， 发现明显低于等效电池的响应， 人类起源 这些研究有可能迅速转化为 用于治疗人类疾病的治疗应用。